Literature DB >> 83285

The association between undifferentiated nasopharyngeal carcinoma and Epstein-Barr virus shown by correlated nucleic acid hybridization and histopathological studies.

M Andersson-Anvret, G Klein, N Forsby, W Henle.   

Abstract

All of 51 undifferentiated carcinomas of the nasopharynx were EBV-DNA-positive and, in the few tests performed, EBNA-positive as well. Most of these patients also had high anti-EBV [VCA and EA (D)] antibody titres. Of four patients that had somewhat differentiated NPCs, two were EBV-DNA-positive with a corresponding serological picture, whereas two were negative with an EBV serology comparable to that of healthy donors. Of seven lymphomas localized in the nasopharynx, one was EBV-DNA-positive and corresponded histologically to Burkitt's lymphoma, whereas six others were EBV-DNA-negative. Fourteen head and neck carcinomas outside the nasopharynx were all EBV-DNA-negative. These results confirm the consistent and unique association of EBV DNA with undifferentiated carcinomas of the nasopharynx.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83285

Source DB:  PubMed          Journal:  IARC Sci Publ


  3 in total

1.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

2.  The descriptive epidemiology of pharyngeal cancer in Scotland.

Authors:  G J MacFarlane; T V Evstifeeva; C Scully; P Boyle
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

3.  Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China.

Authors:  Y M Zheng; P Tuppin; A Hubert; D Jeannel; Y J Pan; Y Zeng; G de Thé
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.